Adicet Bio Inc

NASDAQ ACET

Data sourced from

and

Download Data

Adicet Bio Inc Invested Capital for the quarter ending March 31, 2024: USD 278.96 M

Adicet Bio Inc Invested Capital is USD 278.96 M for the quarter ending March 31, 2024, a -3.75% change year over year. Invested capital represents the total amount of capital invested in a company's operations, including both equity and debt. It is calculated by subtracting the sum of current liabilities (excluding short-term debt) from the total assets of a company. Invested capital reflects the long-term financial resources employed in the company's operations. It is an important measure to evaluate a company's capital structure and assess the amount of capital invested in its productive assets.

Adicet Bio Inc Invested Capital for the quarter ending March 31, 2023 was USD 289.83 M, a -12.65% change year over year.
Adicet Bio Inc Invested Capital for the quarter ending March 31, 2022 was USD 331.78 M, a 28.53% change year over year.
Adicet Bio Inc Invested Capital for the quarter ending March 31, 2021 was USD 258.14 M.

NASDAQ: ACET

Adicet Bio Inc

CEO	Mr. Chen Schor BA, CPA, CPA, M.B.A., MBA
IPO Date	Jan. 26, 2018
Location	United States
Headquarters	200 Clarendon Street, Boston, MA, United States, 02116
Employees	143
Sector	Healthcare
Industry	Biotechnology

Description

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.

Key trends